Abstract
Central venous access is commonly used in clinical practice for a wide spectrum of procedures, such as hemodialysis, long-term chemotherapy, parenteral nutrition, etc. The main complications limiting the duration of use of central catheters and implantable (subcutaneous) ports include microbial contamination and possible catheter-related bloodstream infections. A novel approach to prophylaxis of the complications using specific antimicrobial solution (taurolidine) as a catheter lock and its possible benefits are reviewed in this paper. Based on the level of evidence for the taurolidine studies conducted to date and our data on antimicrobial susceptibility of pathogens causing bloodstream infections, authors provide pharmacokinetic and pharmacodynamic rationale for wide use of this catheter lock approach.
-
1.
Eggiman P., Pittet D. Epidemiology and impact of infections associated with use of intravascular devices. In: Seifert H., Jansen B., Farr B.M. editors. Catheter-related infections. 2nd ed. New York: Marcel Dekker; 2004. p.1-22.
-
2.
Richards M., Edwards J., Culver D., et al. Nosocomial infections in medical intensive care units in the United States. NNIS. Crit Care Med 1999; 27:887-92.
-
3.
Mermel L.A., Allon M., Bouza E., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infection diseases society of America. CID 2009; 49:1-45.
-
4.
Бережанский Б.В. Оптимизация фармакотерапии и профилактики инфекций, связанных с центральным венозным катетером в отделениях реанимации и интенсивной терапии. Автореф. дис. канд. мед. наук. Смоленск, 2008. 22с.
-
5.
Sherertz R.G. Pathogenesis of vascular catheter infections. In: Waldvogel F.A., Bisno A.L. editors. Infections associated with indwelling medical devices. 3rd ed. Washington, D.C.: ASM Press; 2000. p.111-25.
-
6.
Raad I. Intravascular-catheter-related infections. Lancet 1998; 351:893-8.
-
7.
Costerton J.W. Stewart P.S., Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318-22.
-
8.
Stewart P.S., Costerton J.W. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358:135-8.
-
9.
Ceri H., Olson M.E., Stremick C., et al. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilm. J Clin Microbiol 1999; 37:1771-6.
-
10.
Eiff C.V., Heilmann C., Peters G. New aspects in the molecular basis of polymer-associated infections due to staphylococci. Eur J Clin Microbiol Infect Dis 1999; 18:843-6.
-
11.
Sherertz R., Ely W., Westbrook D. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann Intern Med 2000; 132:641-8.
-
12.
Saint S., Savel R., Matthay M. Enhancing the safety of critically patients by reducing urinary and central venous catheter-related infections. Am J Resp Crit Care Med 2002; 165:1475-9.
-
13.
Burn-Busson C. New technologies and infection control practices to prevent intravascular catheter-related infections. Am J Resp Crit Care Med 2001; 164:1557-8.
-
14.
Mermel L. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 133:391-402.
-
15.
De Gaudio A., Di Filippo A. Device-related infections in critically ill patient. Part 1: prevention of catheter-related bloodstream infections. J Chemother 2003; 5:419-27.
-
16.
Gnass S., Barboza L., Bilicich D. Prevention of central venous catheter-related bloodstream infections using non-technologic strategies. Infect Control Hosp Epidemiol 2004; 25:675-7.
-
17.
O'Grady N., Alexander M., Dellenger E., et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2002; 35:1281-307.
-
18.
Collin G. Decreasing catheter colonization through the use of antiseptic-impregnated catheter. Chest 1999; 115:1632-40.
-
19.
Darouiche R. Anti-infective efficacy of silver-coated medical prostheses. Clin Infect Dis 1999; 29:1371-7.
-
20.
Arepally G., Cines D.B. Heparin-induced thrombocytopenia and thrombosis. Clin Rev Allergy Immunol 1998; 16:237-47.
-
21.
Elliot T.S.J., Curran A. Effects of heparin and chlorbutol on bacterial colonization of intravascular cannulae in an in vitro model. J Hosp Infect 1989; 14:193-200.
-
22.
Mermel L., Parenteau S. Efficacy of the biolink catheter lock solution for dialock haemodialysis access port and catheters. Infect Control Hosp Epidemiol 2000; 21:86-174.
-
23.
Mermel M.A., Stolz S.M., Maki D.G. Surface antimicrobial activity of heparin-bonded and antiseptic-impregnated vascular catheters. J Infect Dis 1993; 167:920-4.
-
24.
Crnich C., Maki D. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. II. Long-term devices. Clin Infect Dis 2002; 34:1362-8.
-
25.
D'Agata E.M.C. Antimicrobial-resistant, gram-positive bacteria among patient undergoing chronic hemodialisis. Clin Infect Dis 2002; 35:1212-8.
-
26.
Centers for disease control and prevention. S. aureus resistant to vancomycin – United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7.
-
27.
Simon A., Groger N., Wilkesmann A., et al. Restricted use of glycopeptides in paediatric cancer patient with fever and neutropenia. Int J Antimicrob Agents 2006; 28:417- 22.
-
28.
Waser P.G., Sibler E. Taurolidine – a new concept in antimicrobial chemotherapy. In: Harms A.F. editor. Innovative approaches in drug research. Amsterdam: Elsevier Science Publishers B.V.; 1986. p.155-69.
-
29.
Erb F., Imbenotte M., Huveene J. Structural investigation of a new organic antimicrobial: taurolidine analytical study and application to identification and quantitation in biological fluids. Eur J Drug Metab Pharmacokinet 1983; 8:163-73.
-
30.
Gormann S.P., McCafferty D.F., Woolfson A.D., et al. Reduced adherence of micri-organism to human mucosal epithelial cells following treatment with Taurolin®, a novel antimicrobial agent. J Appl Bacteriol 1987; 62:315- 20.
-
31.
Calabresi P., Goulette F.A., Darnowski J.W. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 2001; 61:6816-21.
-
32.
Willatts S.M. Radford S., Leitermann M. Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind study. Crit Care Med 1995; 23:1033-9.
-
33.
Blenkharn J.I. Prevention of septic complications associated with TNP. J Parenter Enter Nutr 1986; 10:436-7.
-
34.
Quarello F., Forneris G. Prevention of hemodialysis catheter-related bloodstream infection using an antimicrobial lock. Blood Purif 2002; 20:87-92.
-
35.
Torres-Viera C., Thauvin-Eliopoulos C., Souli M., et al. Activities of Taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2000; 44:1720-4.
-
36.
Mittelman M.W., Pelak M., Shah C., et al. Eradication of microbial biofilms with an antimicrobial catheterlock solution. Proceedings of General meeting of ASM, Chicago, USA, 2001. Abstract.
-
37.
TauroPharm GmbH, Waldbuttelbrunn, data on file.
-
38.
Shah C.B., Mittelman M.W., Costerton J.W., et al. Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother 2002; 46:1674-9.
-
39.
Sherertz R.G., Boger M.S., Collins C.A., et al. Comparative in vitro efficacies of various catheter lock solutions. Antimicrob Agents Chemother 2006; 50:1865-8.
-
40.
Sodemann K., Polaschegg H.D., Feldmer B. Two years’ experience with Dialock and CLS (a new antimicrobial lock solution). Blood Purif 2001; 19:251-4.
-
41.
Allon M. Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. Clin Infect Dis 2003; 36:1539-44.
-
42.
Betjes M.G.H., van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant 2004; 19:1546-51.
-
43.
Jurewitsch B., Jeejeebhoy K.N. Taurolidine lock: the key to prevention of recurrent catheter-related bloodstream infection. Clin Nutr 2005; 24:462-5.
-
44.
Simon A., Ammann R.A., Wiszniewsky G., et al. Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infectious Diseases 2008; 8:102.
-
45.
Koldehoff M., Zakrzewski J.L. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patient. Int J Antimicrob Agents 2004; 24:491-5.